We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+11.93%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.58B
AUM Growth
+$232M
Cap. Flow
+$52.5K
Cap. Flow %
0%
Top 10 Hldgs %
43.75%
Holding
149
New
7
Increased
20
Reduced
25
Closed
10

Top Buys

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$60.3M
2
JNJ icon
Johnson & Johnson
JNJ
+$32.4M
3
VTRS icon
Viatris
VTRS
+$16.7M
4
MCK icon
McKesson
MCK
+$14.4M
5
TMO icon
Thermo Fisher Scientific
TMO
+$13.3M

Top Sells

Rank Stock Value
1
AGN
Allergan plc
AGN
+$28.8M
2
MDCO
Medicines Co
MDCO
+$26.2M
3
INCY icon
Incyte
INCY
+$23.8M
4
ABT icon
Abbott
ABT
+$18.6M
5
CNC icon
Centene
CNC
+$17.1M

Sector Composition

Rank Sector Weight
1 Healthcare 91.08%
2 Real Estate 3.31%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
COR icon
26
Cencora
COR
$60.7B
$29.3M 1.13%
330,687
– –
IBB icon
27
iShares Biotechnology ETF
IBB
$9.52B
$22.9M 0.89%
233,910
+60,900
+35% +$5.83M
IDXX icon
28
Idexx Laboratories
IDXX
$44.1B
$20.5M 0.79%
132,352
– –
NBIX icon
29
Neurocrine Biosciences
NBIX
$18.7B
$19.3M 0.75%
446,074
+54,205
+14% +$2.32M
NVS icon
30
Novartis
NVS
$301B
$18.5M 0.72%
277,661
– –
MOH icon
31
Molina Healthcare
MOH
$10.2B
$18.4M 0.71%
402,541
– –
MCK icon
32
McKesson
MCK
$101B
$16.8M 0.65%
113,100
+98,100
+654% +$14.4M
XBI icon
33
State Street SPDR S&P Biotech ETF
XBI
$10.3B
$15.7M 0.61%
226,460
+47,460
+27% +$3.19M
SBRA icon
34
Sabra Healthcare REIT
SBRA
$5.38B
$15.4M 0.6%
550,990
– –
SRPT icon
35
Sarepta Therapeutics
SRPT
$1.64B
$15.1M 0.59%
511,600
+45,300
+10% +$1.4M
GSK icon
36
GSK
GSK
$104B
$15.1M 0.59%
287,200
– –
OHI icon
37
Omega Healthcare
OHI
$15B
$15.1M 0.59%
458,616
– –
PRTK
38
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$14.7M 0.57%
762,581
– –
AZN icon
39
AstraZeneca
AZN
$266B
$14.4M 0.56%
231,900
– –
SNY icon
40
Sanofi
SNY
$103B
$13.8M 0.54%
305,000
– –
DHC
41
Diversified Healthcare Trust
DHC
$2.17B
$13.1M 0.51%
646,554
– –
MPT
42
Medical Properties Trust
MPT
$2.81B
$13M 0.5%
1,007,717
– –
WELL.PRI
43
DELISTED
Welltower Inc.
WELL.PRI
$12.6M 0.49%
200,000
– –
ALNY icon
44
Alnylam Pharmaceuticals
ALNY
$27.4B
$12.5M 0.48%
243,995
– –
ZBH icon
45
Zimmer Biomet
ZBH
$18.4B
$12.5M 0.48%
105,369
– –
CI icon
46
Cigna
CI
$76.1B
$12.3M 0.48%
83,900
-2,500
-3% -$368K
EXEL icon
47
Exelixis
EXEL
$14.1B
$12M 0.46%
551,647
– –
MRUS
48
DELISTED
Merus
MRUS
$11.7M 0.45%
479,150
– –
VTR icon
49
Ventas
VTR
$44.7B
$11.4M 0.44%
175,991
– –
CRL icon
50
Charles River Laboratories
CRL
$11.3B
$11.4M 0.44%
127,100
-500
-0.4% -$42.5K
1
2
3 4 5

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q1 2017 Portfolio in Review

As of Q1 2017, Tekla Capital Management held 149 positions worth $2.58B, up 9.9% from $2.35B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Tekla Capital Management's Q1 2017 filing shows 7 new, 20 increased, 25 reduced and 10 closed positions. Its largest new stake was State Street Health Care Select Sector SPDR ETF: 140,600 shares worth $10.5M. The largest sale was Allergan plc, an estimated $28.8M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, up from 91% a quarter earlier, followed by Real Estate.

  • Tekla Capital Management's largest Q1 2017 buy was State Street Health Care Select Sector SPDR ETF: 140,600 shares worth $10.5M.
  • Tekla Capital Management added most to Amgen in Q1 2017, an estimated $60.3M increase.
  • Tekla Capital Management's biggest Q1 2017 reduction was Allergan plc, cutting an estimated $28.8M.
  • Tekla Capital Management fully exited Medicines Co in Q1 2017, selling an estimated $26.2M.
  • Tekla Capital Management's ten largest holdings make up 44% of its $2.58B portfolio in Q1 2017.
  • Tekla Capital Management opened 7 new positions and closed 10 in Q1 2017.
  • Tekla Capital Management's portfolio value rose 9.9% quarter-over-quarter to $2.58B.

Based on Tekla Capital Management's 13F filing for Q1 2017, filed 12 May 2017.